Spironolactone added to optimal medical treatment will reduce diffuse myocardial fibrosis, diminish atrial remodeling and improve function of left atrium and ventricle, thus preventing recurrent episodes of AF and decrease inflammatory biomarkers as compared with conventional treatment.